Weight
Survodutide
Metabolic
16
Amino acids
Molecular weight
Peptide
Type
Survodutide (BI 456906) is a synthetic acylated 29-amino-acid peptide that acts as a dual agonist at the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R). It reduces energy intake via GLP-1R-mediated appetite suppression and delayed gastric emptying while simultaneously increasing energy expenditure through GCGR-driven hepatic lipolysis. Developed by Boehringer Ingelheim, it is being studied in Phase 3 trials for obesity, type 2 diabetes, MASH, and cardiovascular outcomes.
Top researched benefits
Overview of Survodutide
Survodutide co-activates the glucagon receptor and GLP-1 receptor, producing complementary metabolic effects: GLP-1R agonism suppresses appetite and slows gastric emptying, while GCGR agonism stimulates hepatic lipolysis, reduces visceral fat, and raises energy expenditure. This dual receptor engagement results in greater weight reduction than GLP-1R agonism alone.
weight loss
- 14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
- Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
- Dual mechanism addresses both energy intake and expenditure.
metabolic
- 62% achieved MASH improvement without fibrosis worsening at 4.8mg.
- 63-67% achieved ≥30% liver fat reduction.
- HbA1c reduction up to -1.6% at highest doses.
Typical Dose
0.6 mg starting dose, titrated up to 3.6–6.0 mg
Frequency
once weekly subcutaneous injection
Cycle Duration
Titrate over 10–12 weeks; duration determined by clinical response
Storage
Lyophilized/powder: -20°C for up to 3 years or 4°C for up to 2 years. Reconstituted in bacteriostatic water: 2–8°C; use within 28 days. Do not shake; store away from light.
Chemical Makeup
Key benefits
Produces dose-dependent body weight reductions of up to 16.6% over 46 weeks in Phase 3 trials, with nearly 40% of participants exceeding 20% weight loss at the 4.8 mg dose
Improves MASH without worsening liver fibrosis — 62% of participants in the 4.8 mg group achieved MASH resolution vs. 14% on placebo in Phase 2
Reduces liver fat content by at least 30% in 63–67% of MASH patients, driven by GCGR-mediated hepatic lipolysis
Lowers HbA1c significantly in people with type 2 diabetes through improved insulin and glucagon regulation
Community interest
This peptide is still gaining traction in the community.
GLP-1/GCGR Dual Agonist | Obesity & Metabolic Disease
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoSurvodutide Molecular Information
View the scientifc details of Survodutide.
16
Amino Acids
Survodutide
Ala
Ala
Position 1
Met
Met
Position 2
Ile
Ile
Position 3
Asn
Asn
Position 4
Pyl
Pyl
Position 5
Ala
Ala
Position 6
Cys
Cys
Position 7
Ile
Ile
Position 8
Asp
Asp
Position 9
Pro
Pro
Position 10
Glu
Glu
Position 11
Pro
Pro
Position 12
Thr
Thr
Position 13
Ile
Ile
Position 14
Asp
Asp
Position 15
Glu
Glu
Position 16
Molecular Weight
4231.62DaChain Length
16Amino AcidsType
PeptideSurvodutide Protocols
Survodutide is administered exclusively as a once-weekly subcutaneous injection, consistent with all Phase 2 and Phase 3 clinical trials for obesity and MASH. Preferred injection sites are the abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm, with systematic site rotation required to prevent lipohypertrophy.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Obesity — Weight Loss (Starting Dose) | 0.6 | 1 week range | SubQ |
| Obesity — Weight Loss (Mid Titration) | 2.4 | 1 week range | SubQ |
| Obesity — Weight Loss (High Titration) | 3.6 | 1 week range | SubQ |
| Obesity — Weight Loss (Maintenance) | 4.8 | 1 week range | SubQ |
| MASH / Liver Fibrosis Improvement | 6 | 1 week range | SubQ |
| Metabolic Health / Cardiometabolic Risk Reduction | 4.8 | 1 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Draw 2.0 mL of bacteriostatic water into a sterile syringe
- Insert the syringe needle through the vial stopper and inject the water slowly down the interior wall of the vial — never directly onto the lyophilized powder
- Gently swirl the vial for 30–60 seconds until the powder is fully dissolved — do not shake
- The resulting solution is 5 mg/mL; label the vial with the date and concentration
- Refrigerate the reconstituted vial at 36–46°F and use within 28 days — do not refreeze
- Before each injection, clean the vial stopper with an alcohol swab and allow it to dry completely
- Draw the prescribed weekly dose into a fresh insulin syringe
- Clean the injection site with an alcohol swab and allow to dry
- Pinch the skin and insert the needle at a 45–90° angle depending on body fat level
- Inject the dose slowly and steadily over 2–3 seconds — do not aspirate
- Hold the needle in place for 3–5 seconds after injecting, then withdraw smoothly
- Rotate injection sites with every dose (abdomen, outer thigh, upper outer arm) to prevent lipohypertrophy
- Dispose of the used syringe in a sharps container immediately after injection
Survodutide Cycle
The Survodutide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-4
- Possible nausea, reduced appetite (most common during escalation)
- Week 4-8
- Initial weight loss begins; improved satiety between meals
- Week 8-16
- Progressive weight loss; potential energy level improvements
- Week 16-24
- Approaching steady-state; more consistent effects
- Week 0-0
- Sustained weight loss; average 15-19% by week 46
Dosing tools
Survodutide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Survodutide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Survodutide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Survodutide
- Dosing
- 0.6 mg starting dose, titrated up to 3.6–6.0 mg
- Dosing Frequency
- once weekly subcutaneous injection
- Cycle Duration
- Titrate over 10–12 weeks; duration determined by clinical response
- Storage
- Lyophilized/powder: -20°C for up to 3 years or 4°C for up to 2 years. Reconstituted in bacteriostatic water: 2–8°C; use within 28 days. Do not shake; store away from light.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Side effects
Contraindications
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Stop signs
Severe persistent nausea/vomiting preventing oral intake
Signs of pancreatitis (severe abdominal pain radiating to back)
Allergic reactions (rash, itching, difficulty breathing)
Severe hypoglycemia with insulin/sulfonylureas
Gallbladder symptoms (right upper quadrant pain)
Significant tachycardia or arrhythmias
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
SurvodutideResearch References
Survodutide is a phase 3 compound
Survodutide
Survodutide is a phase 3 compound
Phase 2 Obesity Trial Without Diabetes
387 participants; BMI ≥27 kg/m²; 46 weeks. 14.9% mean weight loss at 4.8mg; 83% achieved ≥5%, 69% achieved ≥10%, 55% achieved ≥15%.
2024
Phase 2 MASH and Fibrosis Trial
293 participants with biopsy-confirmed MASH; 48 weeks. MASH improvement: 62% (4.8mg) vs 14% placebo; 63-67% achieved ≥30% liver fat reduction.
2024
Phase 2 Type 2 Diabetes Trial
Head-to-head vs semaglutide 1.0mg; 16 weeks. Survodutide -8.7% weight loss vs semaglutide -5.3%; HbA1c reduction up to -1.6%.
2023
Calculate peptide dosages
Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.
